Colistin pharmacokinetics: The fog is lifting

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages 30-39

  Couet, W ^a   Gregoire N ^a   Marchand, S ^a   Mimoz, O ^a,b  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Colistin; Critical care patients; Pharmacokinetics; Prodrug; Simulations

Indexed keywords

COLISTIN;

CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SCREENING; GLOMERULUS FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; LIVER FAILURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 83655167235     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03667.x     Document Type: Review

References (23)

1. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
2. Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56: 185-190.
3. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002; 46: 3304-3307.
4. Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 2009; 49: 760-767.
5. Gobin P, Lemaitre F, Marchand S, Couet W, Olivier JC. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography tandem mass spectrometry (LC-MS/MS). Antimicrob Agents Chemother 2010; 54: 1941-1948.
6. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-543.
7. Lim LM, Ly N, Anderson D et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30: 1279-1291.
8. Marchand S, Gobin P, Brillault J et al. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother 2010; 54: 3702-3707.
9. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47: 1766-1770.
10. Ma Z, Wang J, Nation RL et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 2009; 53: 2857-2864.
11. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-840.
12. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia, PA: Lippincott Williams & Wilkins, 1995.
13. Marchand S, Lamarche I, Gobin P, Couet W. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother 2010; 65: 1753-1758.
14. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52: 987-992.
15. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50: 4231- 4232.
16. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-151.
17. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-3436.
18. European Committee on Antimicrobial Susceptibility Testing. Available at: (last accessed 19 June 2008).
19. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-3294.
20. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-4815.
21. Marchand S, Frat JP, Petitpas F et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65: 1836-1837.
22. Couet W, Gregoire N, Gobin P et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89: 875-879.
23. Spapen HD, Honore PM, Gregoire N et al. Convulsions and apnoea in a patient infected with New Delhi metallo-beta-lactamase-1 Escherichia coli treated with colistin. J Infect 2011. July 23 [Epub ahead of print].